7 natural compounds · multi-pathway · preclinical

A multi-compound approach to resistant cancer.

VisionSearch Bio is developing MilanoQ — an investigational oral combination of seven natural compounds, rationally combined to target KRAS/NRAS Q61H-mutant colorectal cancer through several complementary mechanisms. Computational modeling guided the design; wet-lab validation is the next step.

Explore MilanoQ → Read the white paper

Scroll to explore

The problem

Resistant cancers outrun today's medicine.

⚠

Poor durability

Mutation-driven cancers like KRAS/NRAS Q61H relapse frequently, even after aggressive first-line therapy.

☣

Severe toxicity

FOLFOX and FOLFIRI suppress the immune system and cause serious organ stress.

↻

Escape & recurrence

Conventional chemotherapy fails to prevent long-term resistance and disease recurrence.

MilanoQ compound docking with immune activation

Conceptual illustration: a natural compound modeled against a cancer target, with immune cells nearby.

The MilanoQ platform

A multi-pathway approach. From natural compounds.

MilanoQ is an investigational oral combination of seven natural compounds, rationally combined to act on KRAS/NRAS Q61H-mutant colorectal cancer through several complementary biological pathways at once. It is preclinical, and efficacy and safety remain to be established.

01 / RATIONALE

Multi-pathway

Combines compounds reported to act on apoptosis, inflammation (NF-κB) and immune signalling relevant to Q61H-mutant cancer.

02 / APOPTOSIS

Pro-apoptotic

Several components promote programmed tumor-cell death in published preclinical studies.

03 / IMMUNE

Immune-modulatory

Includes compounds with reported effects on anti-tumor immune signalling — to be tested.

04 / DELIVERY

Oral & absorbable

Piperine is included to improve the oral bioavailability of the other compounds.

Design rationale

A rational, multi-target design.

MilanoQ's seven compounds were selected from published preclinical anticancer evidence and prioritized with computational modeling. The items below are hypotheses to be tested in the lab — not results.

What we aim to demonstrate

Hypotheses the Phase I wet-lab work is designed to test

Selective killing of Q61H-mutant vs. wild-type cellsTo be tested

Pro-apoptotic activity of the combinationTo be tested

Immune-modulatory effect (CD8+ signalling)To be tested

Tumor growth inhibition in a live colon-cancer modelTo be tested

Oral bioavailability & tolerabilityTo be tested

ⓘThese are research goals, not results. No efficacy or safety has been established; wet-lab and animal studies are the next milestones.

Planned validation

The areas the Phase I program will test in the lab

Technology stack

Our computational approach.

🔬

Molecular docking

Modeling how each compound may interact with cancer-relevant targets (via our liganx pipeline).

💊

ADMET & drug-likeness

Predicting absorption, metabolism and safety-related properties of each compound.

📚

Literature-based rationale

Each compound selected from published preclinical anticancer evidence.

🧬

Combination modeling

Exploring how the compounds may act through complementary pathways together.

⚖

Prioritization

Using the above to decide which compounds and ratios to test first in the lab.

🧪

Wet-lab validation (next)

In-vitro screening and a live colon-cancer model will test these computational hypotheses.

Pipeline

One platform. Many resistant tumors.

Colorectal cancer (KRAS/NRAS Q61H) is our lead indication. Other hard-to-treat cancers are of future interest, pending validation of the lead program.

Colorectal cancerKRAS / NRAS Q61H — lead indication

Lead / modeled

Lung adenocarcinomaKRAS+

Future interest

Multiple myelomaHematologic

Future interest

Glioblastoma · DIPGCNS / pediatric brain tumor

Future interest

Pancreatic · MelanomaSolid tumors

Future interest

TNBC · NSCLCBreast / lung

Future interest

Colorectal cancer is the active lead; other indications are future directions, not current programs.

Why this matters

How MilanoQ aims to be different.

Attribute	Chemotherapy	Checkpoint / biologics	MilanoQ
Tumor-killing efficacy	High	Variable	Goal — to be tested
Systemic toxicity	Severe	Moderate	Lower-toxicity goal (natural)
Immune activation	Suppresses	Strong	Immune-modulatory (goal)
Resistant-mutation reach	Limited	Limited	Q61H focus
Combination-ready	Limited	Yes	Combination-friendly

ⓘThis table shows design goals and intended comparisons — not established results. Efficacy and safety are still to be tested.

Next steps

Entering partner conversations and seed-stage investment.

CRO-led preclinical validation and, longer-term, IND-enabling studies. The full technical case is in the white paper.

Talk to the team →

📄

MilanoQ White PaperPDF · Investigational natural-compound combination

Download

Get in touch

Let's talk about what comes next.

Whether you're an investor, a CRO, or a strategic partner — we'd love to share the deeper data and discuss collaboration.

✉ Reach us through the form →

🌐 visionsearch.ai